This proposed text is designed to provide a useful and comprehensive resource and state-of-the-art overview to readers about vascular damage potentially induced by antineoplastic drugs. Thanks to more and more effective antineoplastic treatments the survival of cancer patients is enormously increasing, but at the same time it is increasing the burden of related cardiovascular complications that affect morbidity and mortality. On this basis a new branch of cardiology has been developed, that is Cardio-Oncology. The aim is to prevent cardiovascular complications related to cancer therapy and to facilitate and avoid interruption of antineoplastic drugs due to the occurrence of cardiovascular damage. An increasing attention has been given to cardiac damage, while, until today, vascular complications have been poorly evaluated. The aim of this book is to focus on vascular complications related to cancer treatment, to guide the clinician at facing, during his every day practice, cardiovascular toxicity in cancer and hematologic patients. The proposed sections of the book have been structured to review the molecular mechanisms underlying vascular damage induced by new and old treatments, to describe the various manifestations of vascular disease that may range from artery to venous disease (including coronary artery disease, peripheral arterial disease, venous thromboembolism and pulmonary hypertension), and to provide advice to monitor patients undergoing onco-hematologic treatments in order to prevent and eventually manage vascular damage.This book will address resident and fellow physicians, medical oncologists, cardiologists, general practitioners and all those who take care of these patients.All invited authors will be recognized experts in their field, and leading international researchers on these topics. The editor has worked with these expert colleagues on a variety of other projects. The authors will provide their manuscript according to current literature and clinical research studies. The book does not seek to duplicate or replace other current resources. Rather, it will create a comprehensive yet concise resource on this emerging topic that is not adequately covered by any current literature.


Table of contents (20 chapters)

Introduction

Russo, Antonio (et al.)

Pages 1-2

Mechanisms of Cardiovascular Damage Induced by Traditional Chemotherapy

Mercurio, Valentina (et al.)

Pages 3-14

Molecular Mechanisms of Cardiovascular Damage Induced by Anti-HER-2 Therapies

Mercurio, Valentina (et al.)

Pages 15-19

Cardiovascular Damage Induced by Radiotherapy

Galvano, Antonio (et al.)

Pages 21-31

Cardiovascular Damage Induced by Anti-VEGF Therapy

Novo, Giuseppina (et al.)

Pages 33-44

Cardiovascular Damage Induced by Anti-BCR-ABL TKIs

Novo, Giuseppina (et al.)

Pages 45-55

Heart Failure and Left Ventricular Dysfunction

Novo, Giuseppina (et al.)

Pages 57-69

Coronary Artery Disease

Mercuro, Giuseppe (et al.)

Pages 71-82

Peripheral Artery Disease and Stroke

Zito, Concetta (et al.)

Pages 83-92

Valvular Heart Disease

Monte, Ines Paola (et al.)

Pages 93-98

Arterial Hypertension

Spallarossa, Paolo (et al.)

Pages 99-111

Atrial Fibrillation in Cancer

Farmakis, Dimitrios (et al.)

Pages 113-121

Management of QT Prolongation Induced by Anticancer Drugs

Maurea, Nicola (et al.)

Pages 123-132

Pulmonary Hypertension Induced by Anticancer Drugs

Mercurio, Valentina (et al.)

Pages 133-139

Venous Thromboembolism

Maurea, Nicola (et al.)

Pages 141-150

Early Detection of Cardiac Damage

Novo, Giuseppina (et al.)

Pages 151-163

Diagnosis of Cardiac Damage: Role of Stress Echo

Santoro, Ciro (et al.)

Pages 165-172

Early Detection and Monitoring of Vascular Damage

Santoro, Ciro (et al.)

Pages 173-182

Prevention and Clinical Management of Cardiovascular Damage Induced by Anticancer Drugs: Need for Early Biomarkers and Cardio- and Vasculoprotection in Personalized Therapy

Madonna, Rosalinda (et al.)

Pages 183-204

Cardiovascular Damage in Clinical Trials

Bronte, Enrico (et al.)

Pages 205-217